題21-1_畫板 1 副本FA957310F08241619B67FAAC4823E9AE.png)
題21-1_畫板 114202E035D7D448C854A98012E0CB5BF.png)
JHBP (CY) HOLDINGS LIMITED (“JHBP”) was listed on the Main Board of the Hong Kong Stock Exchange on October 7, 2020 (stock code: 6998). JHBP has raised more than HK$ 2.877 billion in this Global Offering, and it is valued at more than HK$11.5 billion after the Listing (before the exercise of the over-allotment option). JHBP’s public offering in Hong Kong was 1200 times oversubscribed.
JHBP is a biotech company listed on the Hong Kong Stock Exchange pursuant to Chapter 18A of the Listing Rules. JHBP was established in December 2007, focusing on developing and commercializing oncology and autoimmune drugs. Drug candidates that JHBP has been developing encompass the top three oncology targets and five out of the ten bestselling drugs globally.
Haiwen has acted as the legal advisor as to PRC law and special consultant as to Hong Kong law of JHBP in this project. Haiwen’s mainland team and Hong Kong team have jointly provided professional legal services for JHBP on the legal issues of PRC and Hong Kong involved in the Global Offering of JHPB, and are highly regarded and recognized by our client and intermediary parties. The sponsors of this IPO are Goldman Sachs, JPMorgan Chase and Jefferies.
Haiwen has been providing full range of legal services for JHBP since 2018, including assisting JHBP in multiple rounds of financing, group restructuring, and providing professional advice and solutions for its general corporate matters.
JHBP (CY) HOLDINGS LIMITED (“JHBP”) was listed on the Main Board of the Hong Kong Stock Exchange on October 7, 2020 (stock code: 6998). JHBP has raised more than HK$ 2.877 billion in this Global Offering, and it is valued at more than HK$11.5 billion after the Listing (before the exercise of the over-allotment option). JHBP’s public offering in Hong Kong was 1200 times oversubscribed.
JHBP is a biotech company listed on the Hong Kong Stock Exchange pursuant to Chapter 18A of the Listing Rules. JHBP was established in December 2007, focusing on developing and commercializing oncology and autoimmune drugs. Drug candidates that JHBP has been developing encompass the top three oncology targets and five out of the ten bestselling drugs globally.
Haiwen has acted as the legal advisor as to PRC law and special consultant as to Hong Kong law of JHBP in this project. Haiwen’s mainland team and Hong Kong team have jointly provided professional legal services for JHBP on the legal issues of PRC and Hong Kong involved in the Global Offering of JHPB, and are highly regarded and recognized by our client and intermediary parties. The sponsors of this IPO are Goldman Sachs, JPMorgan Chase and Jefferies.
Haiwen has been providing full range of legal services for JHBP since 2018, including assisting JHBP in multiple rounds of financing, group restructuring, and providing professional advice and solutions for its general corporate matters.
Beijing ICP No. 05019364-1 Beijing Public Network Security 110105011258
